Opportunity Information: Apply for PAR 17 192
The National Institutes of Health (NIH) grant opportunity titled "Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R21)" (Funding Opportunity Number PAR-17-192) is designed to push forward early-stage, high-impact research that improves how medicines are formulated and delivered for children. The central focus is on the practical reality that children are not just small adults: different pediatric age groups often need different dosage forms, strengths, excipients, and delivery approaches to ensure medicines are safe, effective, and actually acceptable for routine use. This announcement is aimed at addressing research gaps that keep pediatric therapies from being optimized for real-world pediatric care, including challenges tied to swallowing, taste, dosing flexibility, caregiver administration, and age-appropriate delivery methods.
The FOA emphasizes exploratory, novel work under the NIH R21 mechanism, meaning it is oriented toward proof-of-concept ideas, feasibility studies, and innovative approaches rather than large, confirmatory development programs. It specifically encourages applicants to bring in concepts and techniques that are new to pediatric formulation development and testing, including methods that are superior to standard practices in the field. In practical terms, this could include developing or adapting new formulation strategies that better accommodate pediatric needs (for example, enabling accurate dosing across weight ranges, improving palatability without compromising stability, or reducing reliance on excipients that may pose higher risks in infants). It also explicitly supports innovation in pediatric drug delivery systems, which can include technologies or device-formulation combinations intended to improve dosing accuracy, adherence, and usability in children across developmental stages.
The eligible applicant pool is broad, reflecting NIH’s intention to attract ideas from academia, industry, government, and community-linked research settings. Eligible applicants include state, county, city or township governments and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations other than federally recognized governments; public housing authorities and Indian housing authorities; nonprofits with and without 501(c)(3) status (excluding higher education institutions in those categories); for-profit organizations other than small businesses; small businesses; and other entities. The FOA also highlights additional eligible groups and institution types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, non-U.S. (foreign) organizations, Indian/Native American Tribal Governments that are not federally recognized, and U.S. territories or possessions. This inclusive eligibility structure is meant to broaden participation and bring diverse perspectives and capabilities into pediatric drug development challenges.
From an administrative standpoint, the opportunity is categorized as a discretionary grant within the Health, Income Security and Social Services funding activity area, and it is associated with CFDA number 93.865. The opportunity was created on March 29, 2017, and the original closing date listed is May 7, 2020. The award ceiling shown is $200,000, indicating that projects are expected to remain in the smaller, exploratory scope typical of R21 awards. While the number of expected awards is not specified in the provided data, the structure and language of the announcement make clear that NIH is prioritizing innovative, early-stage projects that can open up new directions or overcome persistent barriers in pediatric formulation and delivery science.
Overall, this FOA is essentially a call for creative, technically sound, and pediatric-centered research that improves both the formulation of medicines (how the drug is prepared into a usable dosage form) and the delivery system (how it is administered to and used by children). The emphasis on acceptability across age groups signals that NIH is not only interested in pharmacotechnical success, but also in the real-world factors that determine whether a pediatric product can be used correctly and consistently by patients and caregivers.Apply for PAR 17 192
- The National Institutes of Health in the health, income security and social services sector is offering a public funding opportunity titled "Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.865.
- This funding opportunity was created on 2017-03-29.
- Applicants must submit their applications by 2020-05-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH "Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R21)" (PAR-17-192)
What is the goal of this NIH funding opportunity?
The opportunity supports early-stage, high-impact research to improve how medicines are formulated and delivered for children. It focuses on developing pediatric-appropriate dosage forms, strengths, excipients, and delivery approaches that better match the needs of different pediatric age groups.
What is the funding opportunity number and title?
The funding opportunity is titled "Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R21)" and the Funding Opportunity Number is PAR-17-192.
What grant mechanism is being used?
This opportunity uses the NIH R21 mechanism, which is intended for exploratory and developmental research.
What kind of projects does an R21 support under this FOA?
The FOA emphasizes proof-of-concept ideas, feasibility studies, and other novel, innovative approaches. It is oriented toward early-stage work rather than large, confirmatory development programs.
Why does this FOA emphasize that "children are not just small adults"?
The FOA highlights that pediatric patients across different age groups often require different dosage forms, strengths, excipients, and delivery methods to ensure products are safe, effective, and acceptable for routine use.
What research gaps or practical challenges is this FOA trying to address?
It targets gaps that prevent pediatric therapies from being optimized for real-world care, including swallowing difficulties, taste and palatability issues, dosing flexibility needs, caregiver administration challenges, and age-appropriate delivery methods.
Does the FOA focus more on formulation, delivery systems, or both?
Both. It calls for pediatric-centered research that improves drug formulation (the usable dosage form) and drug delivery systems (how the medicine is administered and used by children).
What does "pediatric formulations" mean in the context of this opportunity?
It refers to research aimed at how a drug is prepared into a usable, age-appropriate dosage form for children, including considerations like dosage strengths, excipients, stability, palatability, and suitability for different pediatric age groups.
What does "pediatric drug delivery systems" mean here?
It refers to technologies or approaches (including device-formulation combinations) intended to improve how medicines are administered to children, with an emphasis on dosing accuracy, adherence, usability, and suitability across developmental stages.
What types of innovations are encouraged?
The FOA encourages concepts and techniques that are new to pediatric formulation development and testing, including approaches that are superior to standard practices in the field.
Are there examples of the kinds of improvements NIH is interested in?
Yes. Examples described include strategies that enable accurate dosing across weight ranges, improve palatability without compromising stability, and reduce reliance on excipients that may pose higher risks in infants.
Is real-world acceptability important for this program?
Yes. NIH emphasizes acceptability across pediatric age groups and highlights real-world factors that affect correct and consistent use by patients and caregivers, not just pharmacotechnical success.
Who is eligible to apply?
Eligibility is broad and includes many organization types across academia, industry, government, and community-linked research settings.
Are state and local government entities eligible?
Yes. Eligible applicants include state governments, county governments, city or township governments, special district governments, and independent school districts.
Are higher education institutions eligible?
Yes. Public and state-controlled institutions of higher education and private institutions of higher education are eligible.
Are tribal entities eligible?
Yes. Federally recognized Native American tribal governments are eligible, and the FOA also lists Native American tribal organizations other than federally recognized governments, and Indian/Native American Tribal Governments that are not federally recognized.
Are nonprofits eligible?
Yes. Nonprofits with and without 501(c)(3) status are listed as eligible (excluding higher education institutions within those nonprofit categories).
Are for-profit organizations eligible?
Yes. For-profit organizations other than small businesses and small businesses are both listed as eligible.
Are housing authorities eligible applicants?
Yes. Public housing authorities and Indian housing authorities are listed as eligible applicants.
Are minority-serving and special-designation institutions included?
Yes. The FOA highlights Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, TCCUs, and related institution types.
Are faith-based or community-based organizations eligible?
Yes. The FOA explicitly includes faith-based or community-based organizations among eligible groups.
Are federal agencies eligible?
Yes. Eligible federal agencies are included in the listed eligible applicants.
Are non-U.S. (foreign) organizations eligible?
Yes. Non-U.S. (foreign) organizations are listed as eligible.
Are U.S. territories or possessions included as eligible entities?
Yes. U.S. territories or possessions are included in the eligibility list.
What is the program area or funding activity category?
The opportunity is categorized as a discretionary grant within the Health, Income Security and Social Services funding activity area.
What is the CFDA number associated with this opportunity?
The associated CFDA number is 93.865.
When was this opportunity created?
The opportunity was created on March 29, 2017.
What is the closing date listed for this opportunity?
The original closing date listed is May 7, 2020.
What is the maximum award amount shown?
The award ceiling shown is $200,000, consistent with the smaller, exploratory scope typical of R21 awards.
How many awards does NIH expect to make?
The number of expected awards is not specified in the provided information.
What overall type of work is NIH prioritizing with this FOA?
NIH is prioritizing creative, technically sound, pediatric-centered research that can open new directions or overcome persistent barriers in pediatric formulation and delivery science.
Browse more opportunities from the same category: Health, Income Security and Social Services
Next opportunity: Integration of Individual Residential Histories into Cancer Research (R01)
Previous opportunity: Supplement Opportunity to Support Population-Based Research Studies of Rare Cancers (Admin Supp)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 17 192
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 17 192) also looked into and applied for these:
| Funding Opportunity |
|---|
| Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R01) Apply for PAR 17 193 Funding Number: PAR 17 193 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R43) Apply for PAR 17 199 Funding Number: PAR 17 199 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R41) Apply for PAR 17 200 Funding Number: PAR 17 200 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Identification of Reproductive-Tract Specific Proteins/Transcripts for the Development of Male and Female Non-Hormonal Contraceptives (R01) Apply for RFA HD 18 002 Funding Number: RFA HD 18 002 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Point of Care Technologies for the Evaluation and Management of Obstetrics, Neonatal, and Pediatric Critical Care Patients, and for Patients with Disorders of Reproductive Tract and Infertility (R43) Apply for RFA HD 18 028 Funding Number: RFA HD 18 028 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| NICHD Exploratory-Developmental Research Grant (R21) Apply for PA 17 259 Funding Number: PA 17 259 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Promoting NICHD Areas of Research for HIV/AIDS in Maternal and Child Health (R01) Apply for PA 17 262 Funding Number: PA 17 262 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Data Coordinating Center for the NICHD Neonatal Research Network (U24) Apply for RFA HD 18 010 Funding Number: RFA HD 18 010 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Small Grants for Secondary Analyses of Existing Data Sets and Stored Biospecimens (R03) Apply for PA 17 299 Funding Number: PA 17 299 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $50,000 |
| Re-Competition of Global Network for Womens and Childrens Health Research (UG1) Apply for RFA HD 18 009 Funding Number: RFA HD 18 009 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Population Dynamics Centers Research Infrastructure Program FY 2018 (P2C) Apply for RFA HD 18 013 Funding Number: RFA HD 18 013 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| National Centers for Translational Research in Reproduction and Infertility (P50) Apply for RFA HD 18 008 Funding Number: RFA HD 18 008 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Typical and Atypical Patterns of Language and Literacy in Dual Language Learners (R01) Apply for PA 17 443 Funding Number: PA 17 443 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $500,000 |
| Typical and Atypical Patterns of Language and Literacy in Dual Language Learners (R21) Apply for PA 17 448 Funding Number: PA 17 448 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Pregnancy in Women with Disabilities (R03) Apply for PA 17 451 Funding Number: PA 17 451 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $50,000 |
| Pregnancy in Women with Disabilities (R01) Apply for PA 17 452 Funding Number: PA 17 452 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Systems Developmental Biology for Understanding Embryonic Development and the Ontogeny of Structural Birth Defects (R01) Apply for PAR 17 454 Funding Number: PAR 17 454 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $499,999 |
| Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings (PATC3H) (UG3/UH3) Apply for RFA HD 18 032 Funding Number: RFA HD 18 032 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Typical and Atypical Patterns of Language and Literacy in Dual Language Learners (R21-Clinical Trial Optional) Apply for PA 18 328 Funding Number: PA 18 328 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Typical and Atypical Patterns of Language and Literacy in Dual Language Learners (R01-Clinical Trial Optional) Apply for PA 18 316 Funding Number: PA 18 316 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 17 192", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.